Skip to main navigation Skip to search Skip to main content

Do asthmatic smokers benefit as much as non-smokers on budesonide/formoterol maintenance and reliever therapy? Results of an open label study

  • Onno C. P. van Schayck*
  • , John Haughney
  • , Michel Aubier
  • , Olof Selroos
  • , Tommy Ekstrom
  • , Juliette Ostinelli
  • , Roland Buhl
  • *Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Background: Studies with inhaled corticosteroids (ICS) in smoking asthmatics have mostly shown poorer treatment responses than in non-smoking asthmatics. Methods: EuroSMART, an open, randomised, 6-month study, compared budesonide/formoterol (Symbicort (R) Turbuhaler (R))(h) maintenance and reliever therapy (Symbicort SMART (R)) at two maintenance doses of budesonide/formoterol (160/4.5 mu g), 1 x 2 and 2 x 2, in patients with asthma who were symptomatic despite treatment with ICS +/- long-acting beta(2)-agonists. The 8424 randomised patients included 886 smokers (11%; aged
Original languageEnglish
Pages (from-to)189-196
Number of pages8
JournalRespiratory Medicine
Volume106
Issue number2
DOIs
Publication statusPublished - Feb 2012

Keywords

  • ACQ-5
  • Asthma
  • Budesonide/formoterol maintenance and reliever therapy
  • Propensity-matched controls
  • Smokers
  • Symbicort SMART

Fingerprint

Dive into the research topics of 'Do asthmatic smokers benefit as much as non-smokers on budesonide/formoterol maintenance and reliever therapy? Results of an open label study'. Together they form a unique fingerprint.

Cite this